Advertisement

How to Study Rare Gynecological Tumors: Trials or Registries?

  • Isabelle Ray-Coquard
  • David M. Gershenson
Chapter

Abstract

The study of rare gynecological tumors presents many challenges. Funding is limited, the pharmaceutical industry has little incentive to develop drugs for rare cancers, patient accrual to trials is frequently prolonged, there is no consensus about the most efficient clinical trial design methodology, and national regulatory requirements currently significantly impair the ability to conduct international trials. In this chapter, we discuss the pros and cons of registries versus clinical trials as strategies to study women with rare gynecological tumors. In putting this topic in perspective, Dr. Ray-Coquard discusses the experience with the French Rare Ovarian Cancer Network, and Dr. Gershenson details the strategies and activities of the Gynecologic Oncology Group’s Rare Tumor Committee.

Keywords

Rare Tumor Clear Cell Carcinoma Gynecologic Oncology Group Granulosa Cell Tumor Uterine Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, et al. Survival for Ovarian Cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. 2012;51(4):441–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Harrison ML, Hoskins P, du Bois A, Quinn M, Rustin GJ, Ledermann JA, et al. Small cell of the ovary, hypercalcemic type – analysis of combined experience and recommendation for management. A GCIG study. Gynecol Oncol. 2006;100(2):233–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer. 1993;71(4 Suppl):1581–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Ray-Coquard I, Le CA. A role for maintenance therapy in managing sarcoma. Cancer Treat Rev. 2012;38:368–78.PubMedCrossRefGoogle Scholar
  5. 5.
    van der Graaf WT, Blay JY, Chawla SP, Kim BG, Bui BN, Casali P, et al. PALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—an EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol. 2011;29:abstract LBA10002.Google Scholar
  6. 6.
    Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do ovarian clear cell carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109(3):370–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Infectious Diseases Society of America. Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts. Clin Infect Dis. 2009;49:328–35.CrossRefGoogle Scholar
  8. 8.
    National Institutes of Health: Office of Rare Disease Research. Rare diseases and related terms. http://rarediseases.info.nih.gov/RareDiseaseList.aspx. 2012.
  9. 9.
    Public Law 97–414. The Orphan Drug Act. 1983.Google Scholar
  10. 10.
    Public Law 107–280. The Rare Diseases Act. 2002.Google Scholar
  11. 11.
    Division of Cancer Prevention and Control (DCPC). Rare cancers: challenges for cancer prevention and treatment. 2009. http://dcp.cancer.gov/programs-resources/groups/cb/events/20091210.
  12. 12.
    National Research Council. Rare diseases and orphan products: accelerating research and development. Washington, DC: The National Academies Press; 2011.Google Scholar
  13. 13.
    Ray-Coquard I, Weber B, Lotz JP, Tournigand C, Provencal J, Mayeur D, et al. Management of rare ovarian cancers: the experience of the French website “observatory for rare malignant tumours of the ovaries” by the GINECO group: interim analysis of the first 100 patients. Gynecol Oncol. 2010;119(1):53–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Donabedian A. The seven pillars of quality. Arch Pathol Lab Med. 1990;114(11):1115–8.PubMedGoogle Scholar
  15. 15.
    Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. J Clin Oncol. 2007;25(20):2944–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ. Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells. Mol Endocrinol. 2004;18(8):1919–28.PubMedCrossRefGoogle Scholar
  17. 17.
    Ray-Coquard I, Pautier P, Alexandre J, Vacher Lavenu MC, Chen N, Floquet A, Selle F, Pujade Lauraine E, for the TMRO Network & GINECO Group. From a website to a national and regional reference centre network: the French experience for rare ovarian tumors. Ann Oncol Suppl. 2012;28:abstract number 20606.Google Scholar
  18. 18.
    Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DG. Vancouver Ovarian Clear Cell Symposium Speakers. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium. Gynecol Oncol. 2011;121(2):407–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, et al. IL-6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17(8):2538–48.PubMedCrossRefGoogle Scholar
  20. 20.
    Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007;105(2):404–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol. 2010;2010:2010.Google Scholar
  22. 22.
    Kuo K-T, Mao T-L, Jones S, Veras E, Ayhan A, Wang TL, et al. Frequent activating mutations in PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597–601.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Mabuchi S, Kawase C, Altomare DA, Morishiqe K, Hayashi M, Sawada K, et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. 2010;9(8):2411–22.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):945–52.PubMedCrossRefGoogle Scholar
  25. 25.
    Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan clear cell carcinoma study. Int J Gynecol Cancer. 2008;18(5):937–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–43.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Alexandre J, Ray-Coquard I, Selle F, Floquet A, Cottu P, Weber B, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 2010;21(12):2377–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Papadimitriou C, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116(6):1462–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010;117(3):491–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Hess V, A’Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22(6):1040–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Kelemen LE, Köbel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011; 12(11):1071–80.PubMedCrossRefGoogle Scholar
  32. 32.
    Matsuo K, Nishimura M, Bottsford-Miller JM, Huang J, Komurov K, Armaiz-Pena GN, et al. Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 2011;17(16):5367–78.PubMedCrossRefGoogle Scholar
  33. 33.
    Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205(5):480.e1–e8.Google Scholar
  34. 34.
    Schmeler KM, Tao Z, Frumovitz M, Deavers MT, Sun CC, Sood AK, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116(2):269–73.PubMedCrossRefGoogle Scholar
  35. 35.
    Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65(22):10602–12.PubMedCrossRefGoogle Scholar
  36. 36.
    Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108(2):361–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Gershenson DM, Sun CC, Bodurka DC, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114(1):48–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012;125:661–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a 2-tier system. Am J Surg Pathol. 2004;28(4):496–504.PubMedCrossRefGoogle Scholar
  40. 40.
    Singer G, Oldt III R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Wong K-K, Tsang YTM, Deavers MT, Mok SC, Zu Z, Malpica A, et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010;177(4):1611–7.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, et al. 2010 Gynecologic Cancer Inter Group (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer. 2011;21(4):750–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Sleijfer S, Wagner AJ. The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases. J Clin Oncol. 2011;30(9):896–8.CrossRefGoogle Scholar
  44. 44.
    Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348(24):2416–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, et al. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol. 2009;27(30):5109–14.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011;365(18):1653–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Adult Medical OncologyCentre Leon BerardLyonFrance
  2. 2.Gynecologic Oncology and Reproductive Medicine, Department of Gynecologic OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations